Keybank National Association OH Acquires 134,862 Shares of Illumina, Inc. (NASDAQ:ILMN)

Keybank National Association OH grew its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 52.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 392,014 shares of the life sciences company's stock after acquiring an additional 134,862 shares during the quarter. Keybank National Association OH owned 0.25% of Illumina worth $52,385,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc lifted its position in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter worth about $32,000. TD Private Client Wealth LLC lifted its holdings in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after acquiring an additional 141 shares during the period. V Square Quantitative Management LLC boosted its position in shares of Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in Illumina by 73.5% in the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company's stock valued at $59,000 after acquiring an additional 186 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ILMN shares. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Piper Sandler increased their price objective on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Morgan Stanley reduced their target price on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. Finally, Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Illumina currently has an average rating of "Moderate Buy" and an average target price of $149.25.

Illumina Trading Up 0.4 %

Shares of ILMN traded up $0.38 on Thursday, reaching $86.07. 526,850 shares of the company's stock were exchanged, compared to its average volume of 2,595,258. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The stock has a market capitalization of $13.63 billion, a P/E ratio of -11.22, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $120.36 and a two-hundred day moving average price of $132.17.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.